• Sanchez-Vega F.*, Mina M.*, Armenia J.*, Chatila W.K., Luna A., La K.C., Dimitriadoy S., Liu D.L., Kantheti H.S., Saghafinia S., Chakravarty D., Daian F., Gao Q., Bailey M.H., Liang W., Foltz S.M., Shmulevich I., Ding I., Heins Z., Ochoa A., Gross B., Gao J., Zhang H., Kundra R., Kandoth C., Bahceci I., Dervishi L., Dogrusoz U., Zhou W., Shen H., Laird P.W., Way G.P., Greene C.S., Liang H., Xiao Y., Wang C., Iavarone A., Berger A.H., Bivona T.G., Lazar A.J., Hammer G.D., Giordano T., Kwong L.N., McArthur G., Huang C., Tward A.D., Frederick M.J., McCormick F., Meyerson M., The Cancer Genome Atlas Research Network, Van Allen E.M., Cherniack A.D.,
    Ciriello G., Sander C., Schultz N. (2018) Oncogenic Signaling Pathways in The Cancer Genome Atlas . Cell, 173(2), 321-337


    * Co-first authors Co-corresponding authors

  • Battistello E., Katanayeva N., Dheilly E., Tavernari D., Donaldson M.C., Bonsignore L., Thome-Miazza M., Christie A.L., Murakami M.A., Michielin O., Ciriello G., Zoete V., Oricchio E. (2018) Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma . Blood, 131(21), 2345-2356

    Highlights:
    • "The future of kinase inhibitors for DLBCL?"   Sarah E. M. Herman Blood

  • Mina M., Raynaud F., Tavernari D., Battistello E., Sungalee S. , Saghafinia S., Laessle T., Sanchez-Vega F., Schultz N., Oricchio E., Ciriello G. (2017) Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies. Cancer Cell, 32(2), 155-168

    Highlights:
    • "Cliques and Schisms of Cancer Genes"   Peter J. Campbell. Cancer Cell
    • "Conditional selection determines the pathways of cancer evolution"   David Killock.
      Nature Review Clinical Oncology

  • Oricchio E., Katanayeva N., Donaldson M.C., Sungalee S., Pasion J.P., B├ęguelin W., Battistello E., Sanghvi V.R., Jiang M., Jiang Y., Teater M., Parmigiani A., Budanov A.V., Chan F.C., Shah S.P., Kridel R., Melnick A.M., Ciriello G. and Wendel H-G. (2017) Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma, Science Trans. Med., 9, 396

  • Ciriello G., Gatza M.L., Bexk A.H., Wilkerson M.D., Rhie S.K., Pastore A., Zhang H., McLellan M., Yau C., Kandoth C., Bowlby R., Shen H., Hayat S., Fieldhouse R., Lester S.C., Tse G.M.K., Factor R.E., Collins L.C., Allison K.H., Chen Y.Y., Jensen K., Johnson N.B., Oesterreich S., Mills G.B., Cherniack A., Robertson G., Benz C., Sander, C., Laird P.W., Hoadley K.A., King T.A., TCGA Research Network, Perou C.M., (2015) Comprehensive molecular portraits of invasive lobular breast cancer, Cell, 163, 2 506-519

  • Oricchio E., Ciriello G., Jiang M., Boyce M.H., Schatz. J.H., Heguy A., Viale A., de Stanchina E., Teruya-Feldstein J., Bouska A., McKeithan T., Sander C., Tam W., Seshan V.E., Chan J., Chaganti R.S.K & Wendel H.G. (2014) Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. J. Exp. Medicine, 211, 7, 1379-91

  • Ciriello G., Miller L.M., Aksoy B.A., Senbabaoglu Y., Schultz N. & Sander C. (2013) Emerging landscape of oncogenic signatures across human cancers. Nat. Genetics, 45, 10, 1127-1133

  • Supplemental Data
    Access the recommendation on F1000Prime
    This article has been also highlighted in: EurekaAlert Economist HuffingtonPost ScienceDaily

  • Ciriello G., Sinha R., Hoadley K.A., Jacobsen A.S., Reva B., Perou C.M., Sander C. & Schultz N. (2013), The molecular diversity of Luminal A breast tumors. Breast Cancer Res. Treat., 141, 3, 409-420

  • Ciriello G., Cerami E.G., Sander C. & Schultz N. (2012), Mutual Exclusivity Analysis Identifies Oncogenic Network Modules. Genome Res., 22, 398-406

  • Access the recommendation on F1000Prime

* Lab members are in bold



  • The complete list of publications can be found here

Copyright © ciriellolab 2016